文献速递安宁疗护多重用药老年慢病共病管理

长期护理机构有限寿命疾病居民他汀类药物使用普遍

Prevalent Statin Use in Long-Stay Nursing Home Residents with Life-Limiting Illness.
PubMed 文献 · J Am Geriatr Soc · 2020-02-14

结果显示34%的居民仍在使用他汀,其中65-75岁组使用率为44.0%,75岁以上组为31.1%。在预后不足6个月的居民中,65-75岁和75岁以上组使用率分别为23%和12%。

要点

  • 超过三分之一的有限寿命疾病长期护理居民仍被处方他汀。
  • 高龄(>75岁)和预后<6个月者他汀使用率仍分别达31.1%和12%-23%。
  • 少数族裔、合并用药>5种及动脉粥样硬化性心血管病或危险因素与他汀使用正相关。

核心结论

  • 尽管患有有限寿命疾病,超过三分之一的临床状况不佳的长期护理机构居民仍在使用他汀。
  • 在接近生命终末期的高龄人群中,继续他汀治疗的获益存疑。
  • 可能有必要在护理机构环境中开展他汀减处方工作。

研究设计与样本

  • 横断面研究,数据来源于美国医疗保险和医疗补助服务中心认证的护理机构。
  • 通过Medicare Part D索赔数据评估2016年9月30日有处方供应的他汀使用情况,回溯期为90天。

主要发现

  • 34%的有限寿命疾病居民被处方他汀。
  • 65-75岁居民他汀使用率为44.0%,其中高强度他汀占11.1%。
  • 75岁以上居民他汀使用率为31.1%,其中高强度他汀占5.4%。
  • 在预后不足6个月的居民中,65-75岁组他汀使用率为23%,75岁以上组为12%。
  • 他汀使用率因有限寿命疾病的定义不同而变化。

关键数值与推荐

  • 他汀使用定义为通过Medicare Part D索赔获得处方供应,分为低-中等强度(每日剂量降低LDL-C<30%-50%)和高强度(每日剂量降低LDL-C>50%)。
  • 有限寿命疾病通过基于证据的标准操作化定义,以识别进展性终末疾病或预后有限(<6个月)者。
  • 与2016年9月30日有处方供应、回溯90天的Medicare Part D索赔数据相关。

临床怎么用

  • 在长期护理机构中,对有限寿命疾病居民应评估他汀继续使用的获益,考虑减处方。
  • 尤其对高龄(>75岁)和预后<6个月的居民,他汀治疗获益存疑,需个体化决策。
  • 关注合并用药>5种、少数族裔及合并动脉粥样硬化性心血管病或危险因素者,这些因素与他汀使用正相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the prevalence and factors associated with statin pharmacotherapy in long-stay nursing home residents with life-limiting illness. DESIGN: Cross-sectional. SETTING: US Medicare- and Medicaid-certified nursing home facilities. PARTICIPANTS: Long-stay nursing home resident Medicare fee-for-service beneficiaries aged 65 years or older with life-limiting illness (n = 424 212). MEASUREMENTS: Prevalent statin use was estimated as any low-moderate intensity (daily dose low-density lipoprotein-cholesterol [LDL-C] reduction <30%-50%) and high-intensity (daily dose LDL-C reduction >50%) use via Medicare Part D claims for a prescription supply on September 30, 2016, with a 90-day look-back period. Life-limiting illness was operationally defined to capture those near the end of life using evidence-based criteria to identify progressive terminal conditions or limited prognoses (<6 mo). Poisson models provided estimates of adjusted prevalence ratios and 95% confidence intervals for resident factors. RESULTS: A total of 34% of residents with life-limiting illness were prescribed statins (65-75 y = 44.0%, high intensity = 11.1%; >75 y = 31.1%, high intensity = 5.4%). Prevalence of statins varied by life-limiting illness definition. Of those with a prognosis of less than 6 months, 23% of the 65 to 75 and 12% of the older than 75 age groups were on statins. Factors positively associated with statin use included minority race or ethnicity, use of more than five concurrent medications, and atherosclerotic cardiovascular disease or risk factors. CONCLUSION: Despite having a life-limiting illness, more than one-third of clinically compromised long-stay nursing home residents remain on statins. Although recent national guidelines have expanded indications for statins, the benefit of continued therapy in an advanced age population near the end of life is questionable. Efforts to deprescribe statins in the nursing home setting may be warranted. J Am Geriatr Soc 68:708-716, 2020.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Mack DS, Tjia J, Hume AL, et al. Prevalent Statin Use in Long-Stay Nursing Home Residents with Life-Limiting Illness. J Am Geriatr Soc. 2020. PMID: 32057091. doi:10.1111/jgs.16336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。